Panax Pharmaceutical Ltd., Sangen Pharmaceutical Co. deal

PANX and privately held Sangen will merge contingent upon the raising of $10-$15 million in a private direct offering.

PANX's lead product

Read the full 222 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE